Argos Therapeutics (ARGS) Misses Q2 EPS by 15c

Argos Therapeutics (NASDAQ: ARGS) reported Q2 EPS of ($0.95), $0.15 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $107 thousand versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• XP Inc eyes US banking license as next business step
• L3Harris CEO steps down amid conduct review, shares drop